The three leading AI labs (Anthropic, OpenAI, and Google DeepMind) are joining forces to implement safety measures targeting the biological applications of their models. In June 2026, the CEOs of all three companies signed an open letter calling on the US Congress to mandate screening and recordkeeping requirements for synthetic DNA and RNA providers. Google DeepMind launched its bioresilience initiative on July 16, pairing trusted researchers with rapid-deployment drug design engines. Anthropic announced in August 2026 that it had reduced false-positive blocks on benign biology queries by approximately 85%, while maintaining stricter restrictions on professional workflows related to drug development. OpenAI has had its own framework since 2025 with its Preparedness Framework, which encompasses biodefense initiatives and drug success prediction tools.
Source: Read the original article
